Literature DB >> 16192424

Increased apical targeting of renal epithelial sodium channel subunits and decreased expression of type 2 11beta-hydroxysteroid dehydrogenase in rats with CCl4-induced decompensated liver cirrhosis.

Soo Wan Kim1, Uffe K Schou, Christian D Peters, Sophie de Seigneux, Tae-Hwan Kwon, Mark A Knepper, Thomas E N Jonassen, Jørgen Frøkiaer, Søren Nielsen.   

Abstract

It was hypothesized that dysregulation of renal epithelial sodium channel (ENaC) subunits and/or 11beta-hydroxysteroid dehydrogenase (11betaHSD2) may play a role in the increased sodium retention in liver cirrhosis (LC). Experimental LC was induced in rats by CCl(4) (1 ml/kg, intraperitoneally, twice a week) for 12 wk (protocol 1) or for 11 wk (protocol 2). In both protocols, one group of rats with cirrhosis showed significantly decreased urinary sodium excretion and urinary Na/K ratio (group A), whereas a second group exhibited normal urinary sodium excretion (group B) compared with controls, even though extensive ascites was seen in both groups of rats with cirrhosis. In group A, protein abundance of alpha-ENaC was unchanged, whereas beta-ENaC abundance was decreased in the cortex/outer stripe of outer medulla compared with controls. The gamma-ENaC underwent a complex change associated with increased abundance of the 70-kD band with a concomitant decrease in the main 85-kD band, corresponding to an aldosterone effect. In contrast, no changes in the abundance of ENaC subunit were observed in group B. Immunoperoxidase microscopy revealed an increased apical targeting of alpha-, beta-, and gamma-ENaC subunits in distal convoluted tubule (DCT2), connecting tubule (CNT), and cortical and medullary collecting duct segments in group A but not in group B. Immunolabeling intensity of 11betaHSD2 in the DCT2, CNT, and cortical collecting duct was significantly reduced in group A but not in group B, and this was confirmed by immunoblotting. In conclusion, increased apical targeting of ENaC subunits combined with diminished abundance of 11betaHSD2 in the DCT2, CNT, and cortical collecting duct is likely to play a role in the sodium retaining stage of liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16192424     DOI: 10.1681/ASN.2004080721

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

1.  Changes of atrial natriuretic Peptide system in rats with puromycin aminonucleoside-induced nephrotic syndrome.

Authors:  Eun Hui Bae; Jongun Lee; Seong Kwon Ma; Soo Wan Kim
Journal:  Korean J Physiol Pharmacol       Date:  2009-02-28       Impact factor: 2.016

2.  Changes in endothelin receptor type B and neuronal nitric oxide synthase in puromycin aminonucleoside-induced nephrotic syndrome.

Authors:  Eun Hui Bae; Soo Wan Kim
Journal:  Korean J Physiol Pharmacol       Date:  2010-08-31       Impact factor: 2.016

Review 3.  ANP-induced signaling cascade and its implications in renal pathophysiology.

Authors:  Franziska Theilig; Qingyu Wu
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-28

4.  Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade.

Authors:  Sophie C Lütken; Soo Wan Kim; Thomas Jonassen; David Marples; Mark A Knepper; Tae-Hwan Kwon; Jørgen Frøkiaer; Søren Nielsen
Journal:  Am J Physiol Renal Physiol       Date:  2009-09-23

5.  Alterations of bone marrow sinusoidal endothelium in rat and patients with liver cirrhosis.

Authors:  Song Zhao; Ying-Mei Fu; Xiu-Fen Li; Zhan-Feng Jin; Rui-Bo Zhao; Qi Huang; Feng-Min Zhang; Wei-Hui Zhang
Journal:  Dig Dis Sci       Date:  2009-04-01       Impact factor: 3.199

6.  Sodium-pump gene-expression, protein abundance and enzyme activity in isolated nephron segments of the aging rat kidney.

Authors:  Pnina Scherzer; Anca Gal-Moscovici; David Sheikh-Hamad; Mordecai M Popovtzer
Journal:  Physiol Rep       Date:  2015-06

Review 7.  Dysregulation of ENaC in Animal Models of Nephrotic Syndrome and Liver Cirrhosis.

Authors:  Soo Wan Kim
Journal:  Electrolyte Blood Press       Date:  2006-03

8.  Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.

Authors:  Victoria K Snowdon; Neil J Lachlan; Anna M Hoy; Patrick W F Hadoke; Scott I Semple; Dilip Patel; Will Mungall; Timothy J Kendall; Adrian Thomson; Ross J Lennen; Maurits A Jansen; Carmel M Moran; Antonella Pellicoro; Prakash Ramachandran; Isaac Shaw; Rebecca L Aucott; Thomas Severin; Rajnish Saini; Judy Pak; Denise Yates; Neelesh Dongre; Jeremy S Duffield; David J Webb; John P Iredale; Peter C Hayes; Jonathan A Fallowfield
Journal:  PLoS Med       Date:  2017-02-28       Impact factor: 11.069

9.  Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats.

Authors:  Eun Hui Bae; In Jin Kim; Ji Hong Song; Hong Sang Choi; Chang Seong Kim; Gwang Hyeon Eom; Inkyeom Kim; Hyunju Cha; Joong Myung Cho; Seong Kwon Ma; Soo Wan Kim
Journal:  Int J Mol Sci       Date:  2019-01-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.